WATCH: Dr. Bryan Ardis – Hospital Protocols Are Killing COVID-19 Patients By Prescribing Remdesivir

Several times I’ve noted at WLT that COVID-19 is NOT a “Pandemic of the Unvaccinated.”

The most appropriate term is “Pandemic of Medical Malpractice.”

Hospital protocols, and not COVID-19, have accounted for a significant portion of deaths.

One of the biggest culprits is the drug Remdesivir.

The antiviral drug manufactured by Gilead Sciences has remained a central component of the standard hospital protocol for COVID-19 patients.

But the toxic drug is responsible for catastrophic side effects like multi-organ-dysfunction syndrome and kidney failure.

None other than Anthony Fraudci and his NIH cronies were behind pushing the dangerous drug for COVID-19 patients.

Remdesivir Background

To understand the severity of this scandal, let’s briefly review some background of how Remdesivir came into use for COVID-19.

Remdesivir is a nucleotide analogue prodrug originally developed for the treatment of Ebola virus.

A New England Journal of Medicine study claimed that a single United States COVID-19 patient showed improvement after taking Remdesivir.

Coincidentally, the Wuhan Institute of Virology sought a patent for the use of Remdesivir.

But at the height of COVID-19, the NIH picked Remdesivir as the gold standard treatment for COVID-19.

Anthony Fraudci cited the drug’s effectiveness against Ebola as the reasoning for its use against this novel coronavirus.

Fraudci used this New England Journal of Medicine study to back his claims.

A closer look at this study below:

MORTALITY

On August 9, 2019, when 681 patients had been enrolled, the data and safety monitoring board conducted an interim analysis on data from 499 patients and, on the basis of two observations, recommended terminating random assignment to ZMapp and remdesivir.

Remdesivir was pulled from the study due to 53.1% of recipients dying from the drug.

Who supported that study?

The NIH & NIAID.

Another New England Journal of Medicine study Fraudci used to push Remdesivir as a COVID-19 treatment analyzed 53 patients from the United States, Canada, Europe, and Japan.

This is what the study found:

Seven of the 53 patients (13%) died after the completion of remdesivir treatment, including 6 of 34 patients (18%) who were receiving invasive ventilation and 1 of 19 (5%) who were receiving noninvasive oxygen support (see the Supplementary Appendix for case narratives). The median interval between remdesivir initiation and death was 15 days (interquartile range, 9 to 17).

cont.

A total of 32 patients (60%) reported adverse events during follow-up (Table 2). The most common adverse events were increased hepatic enzymes, diarrhea, rash, renal impairment, and hypotension. In general, adverse events were more common in patients receiving invasive ventilation. A total of 12 patients (23%) had serious adverse events. The most common serious adverse events — multiple-organ-dysfunction syndrome, septic shock, acute kidney injury, and hypotension — were reported in patients who were receiving invasive ventilation at baseline.

Despite these alarming studies, Remdesivir was pushed on the general public as the standard hospital protocol for COVID-19 patients.

Cheap, off-label drugs like Hydroxychloroquine (HCQ) and Ivermectin were targeted in a vicious smear campaign.

The patents for HCQ and Ivermectin expired decades ago, meaning they don’t line the pockets of pharmaceutical companies and hospital executives.

The toxicity and catastrophic kidney damage caused by Remdesivir provided the ultimate setup to blame deaths caused by the drug on COVID-19.

And the federal health agencies made a fortune buying the stock of Remdesivir, an experimental drug at the time.

Remdesivir was so deadly in the Ebola trial that researchers had to SUSPEND its use in trials. Today it is the standard of care for covid in ever hospital at $3000 a pop https://t.co/cAB19cB7HM

— Daniel Horowitz (@RMConservative) November 15, 2021

https://twitter.com/anisaz9_basit/status/1458108059008393220

Pete Santilli w/ Dr. Bryan Ardis In Depth Discussion About Hospital Treatment Protocol That killed 100k+ In the US! *ReMdiSivir 🚨👀🚨#HCQWorks #IvermectinsavesLives #DoNotComply #FauciLied https://t.co/sVkXffOy4Z

— MAGA Madmacflier 🗣️🇺🇸 (@1madmacflier) September 19, 2021

Watch Dr. Bryan Ardis with the breakdown on Rumble:

The Blaze highlighted how Remdesivir is the greatest scandal of the “pandemic:”

Researchers from the Yale School of Medicine posted a preprint study in which they discovered a mutated version of SARS-CoV-2 that appears to have redeveloped in a previously infected immunocompromised woman who was treated with remdesivir. Researchers were able to sequence the genome in a way that made it clear it was related to the remdesivir use in the patient. The patient was later cured by monoclonal antibodies. “This case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with SARS-CoV-2 infection,” the study’s authors wrote.

Obviously, this mutation appears to be a rare find, but why would we run the risk of spending $3,000 a person on a therapeutic that doesn’t work anyway if it may create immune escape?

Which raises the question: Why are we not treating everyone early with therapeutics like Regeneron, ivermectin, hydroxychloroquine, and other proven safe, cheap, and effective drugs that don’t case renal failure like remdesivir and don’t run the risk of inducing mutations? This is particularly important for those who are immunocompromised. The last thing people who already have fragile organs should be taking is remdesivir.

In many respects the fact that remdesivir was ever approved and is still the only standard of care, as it kills patients and lines the pockets of both hospitals and the maker, Gilead, is possibly the worst scandal of this entire ordeal. On Feb. 5, Reuters reported that none other than the Wuhan Institute of Virology of the China Academy of Sciences sought a patent on Gilead’s remdesivir, a failed drug repurposed from treatment of Ebola, based on the alleged improvement of a single individual COVID patient reported in the New England Journal of Medicine. Incidentally, the only drug ever approved for COVID was developed by Dr. Ralph Baric’s lab at UNC Chapel Hill, the same lab that applied for the coronavirus spike protein gain-of-function research and is suspected by many to be behind the creation of this virus.